General Medicine & Smart Drugs Section

Section Policy:

The General Medicine section of MEFJ aims to publish high-quality research, case studies, and reviews that address broad and interdisciplinary aspects of human health and clinical care, with a special emphasis on the integration of emerging technologies, particularly Artificial Intelligence (AI), into medical practice.

Key Areas of Interest

• Artificial Intelligence in Medicine: Exploring the role of ChatGPT and other AI-driven chatbots in clinical management, research, and patient communication, including benefits, limitations, and ethical implications.
• Medical Education and Training: Enhancing traditional learning using AI tools for interactive, adaptive, and personalized medical education.
• Clinical Applications of AI: Practical use in areas such as clinical toxicology, medical imaging, diabetes research, and automated medical documentation.
• Drug Discovery and Development: AI-enabled discovery of drug-like molecules, optimization of therapeutic design, and faster development pipelines.
• Ethical and Legal Implications: Addressing concerns related to privacy, data bias, and regulation of AI in healthcare systems.
• Future Directions and Challenges: Emphasizing the need for innovation, transparency, human-centered care, and collaboration in AI adoption.

Expanded Scope

• Clinical diagnosis and evidence-based medicine
• Smart drug delivery systems
• Biotechnology in therapeutic innovation
• Medical pathology and histopathology studies
• Pharmacogenomics and personalized medicine
• Novel case reports and clinical procedures with educational or diagnostic value

For the complete journal aims and scope, please visit our Aim & Scopes page.